Gilead Sciences (GILD - Free Report) just released its first quarter fiscal 2017 financial results, posting earnings of $2.23 per share and revenues of $6.5 billion. GILD is a #2 (Buy) on the Zacks Rank, and is down 1.66% to $6.45 per share in trading shortly after its earnings report was released.
Gilead:
Missed earnings estimates. The company reported earnings of $2.23 per share, falling short of the Zacks Consensus Estimate of $2.25 per share. This number excludes 18 cents from non-recurring items.
Missed revenue estimates. The company saw revenue figures of $6.5 billion, missing the Zacks Consensus Estimate of $6.66 billion and declining 16.4% year-over-year.
Gilead reported total product sales of $6.4 billion for Q1, compared to $7.7 billion in the same period in 2016. Antiviral product sales, which include sales of its HIV, chronic hepatitis B (HBV) and chronic hepatitis C (HCV) products, were $5.8 billion for the first quarter.
Regionally, Product sales in Q1 were $4.5 billion in the United States, $1.3 billion in Europe, and $661 million in other locations.
The company reiterated its full-year 2017 guidance. Gilead expects net product sales in the range of $22.5 billion and $24.5 billion, and product gross margin between 86% and 88%. Diluted EPS is forecasted in the range of 84 cents to 91 cents per share.
Here’s a graph that looks at Gilead’s price, consensus, and EPS surprise:
Gilead Sciences, Inc. is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. They have a broad-based focus on developing and marketing drugs to treat patients with infectious diseases, including viral infections, fungal infections and bacterial infections, and a specialized focus on cancer. They have expertise in liposomal drug delivery technology, a technology that the company uses to develop drugs that are safer, easier for patients to tolerate and more effective.
The Best & Worst of Zacks
Today you are invited to download the full, up-to-the-minute list of 220 Zacks Rank #1 "Strong Buys" free of charge. From 1988 through 2015 this list has averaged a stellar gain of +25% per year. Plus, you may download 220 Zacks Rank #5 "Strong Sells." Even though this list holds many stocks that seem to be solid, it has historically performed 6X worse than the market. See these critical buys and sells free >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Gilead Sciences (GILD - Free Report) just released its first quarter fiscal 2017 financial results, posting earnings of $2.23 per share and revenues of $6.5 billion. GILD is a #2 (Buy) on the Zacks Rank, and is down 1.66% to $6.45 per share in trading shortly after its earnings report was released.
Gilead:
Missed earnings estimates. The company reported earnings of $2.23 per share, falling short of the Zacks Consensus Estimate of $2.25 per share. This number excludes 18 cents from non-recurring items.
Missed revenue estimates. The company saw revenue figures of $6.5 billion, missing the Zacks Consensus Estimate of $6.66 billion and declining 16.4% year-over-year.
Gilead reported total product sales of $6.4 billion for Q1, compared to $7.7 billion in the same period in 2016. Antiviral product sales, which include sales of its HIV, chronic hepatitis B (HBV) and chronic hepatitis C (HCV) products, were $5.8 billion for the first quarter.
Regionally, Product sales in Q1 were $4.5 billion in the United States, $1.3 billion in Europe, and $661 million in other locations.
The company reiterated its full-year 2017 guidance. Gilead expects net product sales in the range of $22.5 billion and $24.5 billion, and product gross margin between 86% and 88%. Diluted EPS is forecasted in the range of 84 cents to 91 cents per share.
Here’s a graph that looks at Gilead’s price, consensus, and EPS surprise:
Gilead Sciences, Inc. is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. They have a broad-based focus on developing and marketing drugs to treat patients with infectious diseases, including viral infections, fungal infections and bacterial infections, and a specialized focus on cancer. They have expertise in liposomal drug delivery technology, a technology that the company uses to develop drugs that are safer, easier for patients to tolerate and more effective.
The Best & Worst of Zacks
Today you are invited to download the full, up-to-the-minute list of 220 Zacks Rank #1 "Strong Buys" free of charge. From 1988 through 2015 this list has averaged a stellar gain of +25% per year. Plus, you may download 220 Zacks Rank #5 "Strong Sells." Even though this list holds many stocks that seem to be solid, it has historically performed 6X worse than the market. See these critical buys and sells free >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on GILD - FREE